根据种族和地理因素分析舒尼替尼在转移性肾细胞癌患者中的耐受性和疗效。 - Suppr

Suppr

超能文献

Sunitinib tolerance and efficacy in patients with metastatic renal cell carcinoma according to ethnic and geographic factors.

作者信息

Zekri Jamal, Imtiaz Saba, Al Mansour Mubarak, Darwish Waseem

机构信息

King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia.

Princess Norah Oncology Center, King Abdulaziz Medical City, Jeddah, Saudi Arabia.

出版信息

Int Urol Nephrol. 2017 Mar;49(3):459-460. doi: 10.1007/s11255-017-1502-5. Epub 2017 Jan 9.

DOI:10.1007/s11255-017-1502-5

PMID:28070728

Abstract

摘要

相似文献

Sunitinib tolerance and efficacy in patients with metastatic renal cell carcinoma according to ethnic and geographic factors.根据种族和地理因素分析舒尼替尼在转移性肾细胞癌患者中的耐受性和疗效。

Int Urol Nephrol. 2017 Mar;49(3):459-460. doi: 10.1007/s11255-017-1502-5. Epub 2017 Jan 9.

Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.舒尼替尼治疗转移性肾嫌色细胞癌患者的疗效

Oncologist. 2016 Oct;21(10):1212-1217. doi: 10.1634/theoncologist.2015-0428. Epub 2016 Jul 5.

Urol Oncol. 2016 Aug;34(8):338.e1-9. doi: 10.1016/j.urolonc.2016.03.010. Epub 2016 Apr 13.

When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report.转移性肾细胞癌转移至胰腺时酪氨酸激酶抑制剂舒尼替尼何时可停用：一例报告

J Med Case Rep. 2018 Mar 20;12(1):80. doi: 10.1186/s13256-018-1597-z.

[Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].索拉非尼与舒尼替尼作为转移性肾细胞癌一线治疗的疗效比较及生存预后因素分析

Zhonghua Zhong Liu Za Zhi. 2018 May 23;40(5):384-389. doi: 10.3760/cma.j.issn.0253-3766.2018.05.012.

Re: A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma.回复：一项针对既往未接受治疗的转移性肾细胞癌患者的舒尼替尼间歇给药II期研究。

J Urol. 2018 Jan;199(1):23-25. doi: 10.1016/j.juro.2017.09.134. Epub 2017 Oct 10.

Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.舒尼替尼在转移性肾细胞癌透析患者中的耐受性。

Clin Genitourin Cancer. 2009 Oct;7(3):E104-6. doi: 10.3816/CGC.2009.n.035.

Sunitinib for metastatic renal cell carcinoma.舒尼替尼治疗转移性肾细胞癌。

Future Oncol. 2010 Sep;6(9):1377-85. doi: 10.2217/fon.10.94.

IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.IMA901，一种多肽癌症疫苗，联合舒尼替尼对比舒尼替尼单药，用于晚期或转移性肾细胞癌（IMPRINT）的一线治疗：一项多中心、开放标签、随机、对照、3 期临床试验。

Lancet Oncol. 2016 Nov;17(11):1599-1611. doi: 10.1016/S1470-2045(16)30408-9. Epub 2016 Oct 3.

Commentary on "Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α." Tsimafeyeu I, Zart JS, Chung B, Kidney Cancer Research Bureau, Moscow, Russian Federation.: BJU Int 2013; 112(1):32-8. [Epub 2013 Jun 7]. doi: 10.1111/bju.12107.关于“舒尼替尼或干扰素-α治疗原发性肿瘤较小的转移性肾细胞癌（RCC）患者的细胞减灭性射频消融术”的述评。齐马费尤 I、扎特 JS、钟 B，俄罗斯联邦莫斯科肾癌研究局。：《英国泌尿学杂志》2013年；112(1):32 - 8。[2013年6月7日在线发表]。doi: 10.1111/bju.12107

Urol Oncol. 2014 May;32(4):514-5. doi: 10.1016/j.urolonc.2013.12.011.

引用本文的文献

Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population.舒尼替尼作为阿拉伯人群转移性肾细胞癌患者一线治疗的疗效及预后因素

JCO Glob Oncol. 2020 Feb;6:19-26. doi: 10.1200/JGO.19.00111.

本文引用的文献

Safety and efficacy of sunitinib in patients from Latin America: subanalysis of an expanded access trial in metastatic renal cell carcinoma.舒尼替尼在拉丁美洲患者中的安全性和有效性：转移性肾细胞癌扩大可及性试验的亚组分析

Onco Targets Ther. 2016 Sep 23;9:5839-5845. doi: 10.2147/OTT.S109445. eCollection 2016.

Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience.舒尼替尼治疗晚期肾细胞癌患者：巴西国家癌症研究所（INCA）的经验。

Int Braz J Urol. 2016 Jul-Aug;42(4):694-703. doi: 10.1590/S1677-5538.IBJU.2015.0226.

Utilization of Sunitinib for Renal Cell Cancer: an Egyptian University hospital experience.舒尼替尼在肾细胞癌治疗中的应用：一家埃及大学医院的经验

Asian Pac J Cancer Prev. 2016;17(7):3161-6.

Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients?舒尼替尼用于转移性肾细胞癌（mRCC）：一个发展中国家的经验。我们的患者表现与西方患者不同吗？

Int Urol Nephrol. 2016 Nov;48(11):1811-1816. doi: 10.1007/s11255-016-1380-2. Epub 2016 Jul 23.

Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.索拉非尼与舒尼替尼作为转移性肾细胞癌患者一线治疗的疗效和安全性：最大规模单中心回顾性分析

Oncotarget. 2016 May 10;7(19):27044-54. doi: 10.18632/oncotarget.7395.

Factors Prognostic for Survival in Japanese Patients Treated with Sunitinib as First-line Therapy for Metastatic Clear Cell Renal Cell Cancer.日本患者接受舒尼替尼一线治疗转移性透明细胞肾细胞癌的生存预后因素。

Asian Pac J Cancer Prev. 2015;16(14):5687-90. doi: 10.7314/apjcp.2015.16.14.5687.

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.舒尼替尼治疗转移性肾细胞癌大型全球扩大可及性试验的最终结果。

Br J Cancer. 2015 Jun 30;113(1):12-9. doi: 10.1038/bjc.2015.196. Epub 2015 Jun 18.

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.肾细胞癌：欧洲肿瘤内科学会临床实践诊断、治疗及随访指南

Ann Oncol. 2014 Sep;25 Suppl 3:iii49-56. doi: 10.1093/annonc/mdu259.

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.舒尼替尼与干扰素α治疗转移性肾细胞癌患者的总生存期及更新结果比较

J Clin Oncol. 2009 Aug 1;27(22):3584-90. doi: 10.1200/JCO.2008.20.1293. Epub 2009 Jun 1.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验